Decreased plasma APOA1 levels are associated with increased severity of placenta accreta spectrum disorders: a nested case-control study
ObjectivePlacenta accreta spectrum (PAS) disorders are a series of gestational diseases, with severe adverse outcomes. Apolipoprotein A1 (APOA1) is a lipid molecule that plays a role in cell invasion, inflammation and immune response. This study aimed to elucidate the relationship between APOA1 and...
Saved in:
Main Authors: | Shuai Zeng, Jiangxue Qu, Hai Jiang, Huifeng Shi, Jie Yan, Yangyu Zhao, Lian Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-07-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2025.1627377/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Placenta Accreta Spectrum (PAS): Risk Factors, Diagnosis, Management, and Complications—Experience in a Tertiary Care Obstetric Centre in North India
by: Sabahat Rasool, et al.
Published: (2025-06-01) -
Current state of the placenta accreta spectrum issue: prospects for organ-preserving treatment
by: M. D. Voronina, et al.
Published: (2025-03-01) -
Surgical management of delivery with placenta accreta spectrum from the perspective of perinatal obstetrics
by: A. Yu. Ralnikova, et al.
Published: (2024-11-01) -
Placenta accreta spectrum. Current diagnostic issues
by: A. E. Volkov, et al.
Published: (2023-01-01) -
Doppler Parameters of Uterine Arteries in the Evaluation of Placenta Accreta in Patients with Placenta Previa
by: Zheng L, et al.
Published: (2025-07-01)